Prescient Therapeutics’ (ASX:PTX) 1H22 marked by key clinical milestones
ASX-listed biopharmaceutical company Prescient Therapeutics Limited (ASX: PTX) is leaving no stone unturned as it progresses towards...
ASX-listed biopharmaceutical company Prescient Therapeutics Limited (ASX: PTX) is leaving no stone unturned as it progresses towards...
Cancer is one of the significant causes of death worldwide. As per the World Health...
Biopharmaceutical company Prescient Therapeutics Limited (ASX: PTX) engaged in evolving personalized therapies for cancer has released its...
To fight the menace of cancer, there have been categorical and highly efficacious progress in...
A clinical-stage oncology company, Prescient Therapeutics (ASX:PTX) has further strengthened its Scientific Advisory Board (SAB) with the...
One of the leading clinical-stage oncology companies, Prescient Therapeutics Limited (ASX:PTX), has been making its...
Prescient Therapeutics Limited (ASX: PTX) has released the results for September quarter of fiscal year...
Prescient Therapeutics Limited (ASX:PTX) is presenting new preclinical data on OmniCAR at the Cell &...
ASX-listed oncology player, Prescient Therapeutics Limited (ASX:PTX) is developing personalised medicines for difficult to treat...
This year, the ASX healthcare index gained a little more than 10% year to date....
This investor centre was built by Reach Markets
©2025 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.